



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address : COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10/590,385	19 June, 2007	MOORHOUSE ET AL.	3403-P10319US

TRASKBRITT, P.C. P.O. BOX 2550 SALT LAKE CITY, UT 84110		EXAMINER	
		PETER J. REDDIG	
ART UNIT	PAPER		
1642	20111107		

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

This is in response to Applicant's petition to accept color drawings/photographs filed on October 25, 2011.

All requirements under 37CFR 1.84(a)(2) are met. Thus, the petition is Granted.

Petition GRANTED.

/Misook Yu/
Supervisory Patent Examiner, Art Unit 1642

EXAMINER'S AMENDMENT

1. An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.

2. Claims 50-58 are currently under consideration and are allowable in view of the following amendments.

3. The application has been amended as follows:

In the claims:

Claim 53 was amended to read as follows:

53. A method for determining the prognosis for an AML-affected subject, said method comprising the steps of: determining, in a sample obtained from the subject, a level of expression of each of at least HGF, FGF 13, MEG3, GABRE and MST1 from cluster #12, corresponding to the AML class of t(15; 17); establishing the similarity of expression levels between the at least HGF, FGF13, MEG3, GABRE and MST1 in the AML-affected subject and the at least HGF, FGF13, MEG3, GABRE and MST1 in subjects selected from the t(15; 17) class; and assigning to the AML-affected subject a prognosis based on the established similarity of expression levels between the at least HGF, FGF13, MEG3, GABRE and MST1 in the AML-affected subject and the at least HGF, FGF13, MEG3, GABRE and MST1 in subjects selected from the t(15; 17) class.

In the specification:

Pages numbered 173-176 of the substitute specification filed 06/13/2011 were deleted.

4. Authorization for this Examiner's Amendment was given in a telephone interview with Daniel J. Morath on November 7, 2011.

5. Any comments considered necessary by applicant must be submitted no later than the payment of the Issue Fee and, to avoid processing delays, should preferably **accompany** the Issue Fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Peter J. Reddig whose telephone number is (571) 272-9031. The examiner can normally be reached on M-F 8:30 a.m.-5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Misook Yu can be reached on (571) 272-0839. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Peter J Reddig/
Primary Examiner, Art Unit 1642